Clinical trials: Diffuse Systemic Sclerosis
Scleroderma, Systemic Sclerosis (SSc)
Evaluating the Effect of Questionnaire Context on the Reporting of Somatic Items Among People With Systemic Sclerosis
There is concern that self-reported depression questionnaires that contain items assessing somatic symptoms may result in biased scores in people with a chronic disease due to symptoms that overlap with their physical disease.
- Conditions
- Scleroderma, Systemic Sclerosis (SSc), Scleroderma (Limited and Diffuse)
- Trial name
- NCT06772896
- Testing
- Reordered PHQ-8
- Where
- 2 sites in Canada
- Volunteers
- 851 people
- Sponsor
- Lady Davis Institute
Scleroderma, Systemic Sclerosis
Duke Scleroderma Clinic Patient Registry
The purpose of the Duke Scleroderma Registry (DSScR) is to obtain information about scleroderma. This information could be used in future research to increase the understanding of disease mechanisms, treatments, and outcomes.
- Trial name
- NCT02851875
- Testing
- Registry
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Scleroderma, Connective Tissue Diseases
Oral Type I Collagen for Relieving Scleroderma
Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing damage to skin and other organs. The purpose of this study is to determine if taking oral bovine type I collagen (CI) will improve the…
- Trial name
- NCT00005675
- Testing
- Oral bovine type I collagen
- Where
- 12 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Sclerosis
Rapamycin vs Methotrexate in Diffuse SSc
This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma.
- Trial name
- NCT00241189
- Testing
- rapamycin, methotrexate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Scleroderma, Systemic Sclerosis
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs.
- Trial name
- NCT00040651
- Testing
- Fludarabine, Cyclophosphamide, Thymoglobulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Diet Habit, Rheumatologic Disease
Rheumatology Diet Study
This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their…
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis
- Trial name
- NCT06339957
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Central Florida
Systemic Sclerosis, Systemic Scleroses, Diffuse
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries.
- Conditions
- Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse
- Trial name
- UPSIDE (NCT04464434)
- Testing
- Upfront autologous HSCT
- Where
- 8 sites in Italy, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Rheumatoid Arthritis, Spondyloarthritis
Pregnancy and Medically Assisted Conception in Rare Diseases
Rare diseases frequently affect women of childbearing age. Pregnancy in these women has become less rare, but remains associated with high levels of complications.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- EGR2 (NCT02450396)
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Inflammatory Myopathies
Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
Systemic sclerosis and inflammatory myopathies, which sometimes combine (scleromyositis), have shared pathophysiological elements.
- Trial name
- SCLEROMYOMICS (NCT04917705)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Early Diffuse Cutaneous Systemic Sclerosis
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- ESOS (NCT02339441)
- Testing
- Methotrexate, Mycophenolate mofetil, Cyclophosphamide
- Volunteers
- 320 people
- Sponsor
- University of Manchester
Scleroderma, Raynaud's Syndrome
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.
- Trial name
- NCT02165111
- Testing
- Onabotulinumtoxin A, sterile saline solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Scleroderma, Localized, Scleroderma, Systemic
Efficacy and Safety of Imatinib in Scleroderma
In vitro studies have shown that imatinib 1mM inhibits strongly the growth of cutaneous fibroblasts. The hypothesis is that imatinib inhibits PDGFR which is known to be a potential target for the molecule, as recently also…
- Trial name
- SCLEROGLIVEC (NCT00479934)
- Testing
- imatinib mesylate
- Where
- 12 sites in France
- Volunteers
- 28 people
- Sponsor
- University Hospital, Bordeaux
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
Scleroderma, Systemic
Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study
The purpose of the study is to assess skin blood flow after non-invasive local administration of treprostinil by using a low-intensity current (i.e.
- Trial name
- TIPPS (NCT01554540)
- Testing
- Cutaneous iontophoresis of treprostinil
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Scleroderma, Systemic, Scleroderma, Diffuse
Effects of FT011 in Systemic Sclerosis
FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).
- Conditions
- Scleroderma, Systemic, Scleroderma, Diffuse, Sclerosis, Systemic
- Trial name
- NCT04647890
- Testing
- FT011
- Where
- 10 sites in Australia, Netherlands and 3 more
- Volunteers
- 30 people
- Sponsor
- Certa Therapeutics
Scleroderma
Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis
Scleroderma is disease believed to be due to immune cells, cells which normally protect the body but are now causing damage to the body. There has not been any treatment that has been effective in treating this disease.
- Trial name
- NCT00282425
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Richard Burt, MD
Scleroderma, Systemic, Scleroderma, Diffuse
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Early phases of systemic sclerosis is characterized by inflammatory and microvasculature alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance vasculogenesis.
- Conditions
- Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
- Trial name
- NCT01347008
- Testing
- Sildenafil citrate
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Federal University of São Paulo
Scleroderma, Systemic Sclerosis
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand…
- Conditions
- Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease
- Trial name
- STAR (NCT02396238)
- Testing
- Celution Device
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Cytori Therapeutics
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines…
- Trial name
- NCT05626751
- Testing
- HZN-825
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 174 people
- Sponsor
- Amgen